Qdenga: Crunch Time For First Product In Parallel Review Route For EU And Non-EU Markets

 
• By Neena Brizmohun

Takeda could soon learn whether the European Medicines Agency will recommend in favor of approving its dengue vaccine, which was reviewed under a new evaluation route that simultaneously targets EU and non-EU countries.

Mosquito
Takeda says dengue was one of the WHO’s top 10 threats to global health in 2019 • Source: Shutterstock: frank60

More from Europe

More from Geography